### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7957421

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE PHARMACEUTI HOLDING CORPORATION	CAL 05/15/2023

#### **RECEIVING PARTY DATA**

Name:	AVENIR WELLNESS SOLUTIONS, INC.
Street Address:	5805 SEPULVEDA BLVD #801
City:	SHERMAN OAKS
State/Country:	CALIFORNIA
Postal Code:	91411

#### **PROPERTY NUMBERS Total: 14**

Property Type	Number
Patent Number:	9044390
Patent Number:	9186386
Patent Number:	9980996
Patent Number:	10092611
Patent Number:	10238705
Patent Number:	10639339
Patent Number:	10624940
Patent Number:	11266702
Patent Number:	11478520
Patent Number:	11344591
Patent Number:	11331358
Application Number:	18048954
Application Number:	17663164
Application Number:	17663065

#### **CORRESPONDENCE DATA**

**Fax Number:** (612)436-9605

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

using a lax number, it provided, it that is unsuccessiul, it will be sent via 03 mai

**Phone:** 6124369643

Email: SKRUSE@CARLSONCASPERS.COM

PATENT

507910296 REEL: 063663 FRAME: 0831

Correspondent Name: GARY J. SPEIER

Address Line 1: CARLSON, CASPERS, VANDENBURGH & LINDQUIST P.A.

Address Line 2: 225 S. SIXTH ST., SUITE 4200

Address Line 4: MINNEAPOLIS, MINNESOTA 55402

NAME OF SUBMITTER:	GARY J. SPEIER
SIGNATURE:	/Gary J. Speier/
DATE SIGNED:	05/17/2023

**Total Attachments: 3** 

source=Assignment\_Avenir FKA Cure Pharm Holding Corp to Avenir#page1.tif source=Assignment\_Avenir FKA Cure Pharm Holding Corp to Avenir#page2.tif source=Assignment\_Avenir FKA Cure Pharm Holding Corp to Avenir#page3.tif

#### PATENT ASSIGNMENT

This Patent Assignment (this "Assignment") is made this <u>15</u> day of <u>May</u>, 2023, by and between Avenir Wellness Solutions, Inc. F/K/A Cure Pharmaceutical Holding Corporation, a Nevada corporation with a place of business located at 1620 Beacon Place, Oxnard, CA 93033 ("Assignor"), and Avenir Wellness Solutions, Inc. a California corporation with a place of business located at 5805 Sepulveda Blvd #801, Sherman Oaks, CA 91411 ("Assignee").

WHEREAS, Assignor owns all right, title, and interest in and to the issued patents and patent applications identified on **Exhibit A** hereto (collectively referred to as the "Patents"); and

WHEREAS, Assignor desires to assign, convey, sell and transfer all right, title, and interest in and to the Patents to Assignee; and

WHEREAS, Assignee is desirous of acquiring from Assignor all right, title, and interest in and to the Patents.

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency, and adequacy of which are hereby acknowledged, Assignor hereby sells, transfers and assigns to Assignee as of the Effective Date the entire right, title and interest in and to the Patents, including, without limitation, all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States (including all provisional and non-provisional applications), and in all foreign countries and jurisdictions based in whole or in part on any of such Invention (including any application for a utility model or an innovation patent application);

all original and reissued patents which have been or shall be issued in the United States and all foreign countries and jurisdictions based in whole or in part on any of such Invention;

including the right to claim priority to the above-identified patent application or applications in relation to subject matter based in whole or in part on the above-identified patent application or applications and any of the foregoing including the right to file foreign applications under the provisions of any convention or treaty;

and including the right to all causes of action, remedies, and other enforcement rights related to the above-identified application or applications, including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the above-identified patent application or applications and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such Invention to the Assignee;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or shall be made to others by the Assignor, and that the full right to convey the same as herein expressed is possessed by the Assignor;

COVENANT, that when requested and without compensation, but at the expense of the Assignee, in order to carry out in good faith the intent and purpose of this Assignment, the Assignors shall take all actions, execute any additional assignments or other documents and to otherwise cooperate as necessary, under the laws of the United States as soon as is practicable after the effective date of this Assignment or as otherwise requested by Assignee, to effectuate, confirm or perfect the assignment and recordation of all rights, title, and interest in and to the Patents.

#### **ASSIGNOR:**

## AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE

PHARMACEUTICAL HOLDING CORPORATION
Joel Bennett
By:
Joel Bennett
Name:
Chief Financial Officer
Title:
ASSIGNEE:
AVENIR WELLNESS SOLUTIONS, INC.
Tool Parriable

Joel Kennett Joel Bennett Name: Chief Financial Officer Title:

# **EXHIBIT A**

**RECORDED: 05/17/2023** 

Title	Serial No.	Filing Date	Patent No.	Issue Date
Pharmaceutical composition and method of manufacturing	14/255,296	04/17/2014	U.S. 9,044,390	06/02/2015
Pharmaceutical composition and method of manufacturing	14/723,980	05/28/2015	U.S. 9,186,386	11/17/2015
Pharmaceutical composition and method of manufacturing	14/694,303	04/23/2015	966'086'6 'S'N	05/29/2018
Pharmaceutical composition and method of manufacturing	15/988,484	05/24/2018	U.S. 10,092,611	10/09/2018
Pharmaceutical composition and method of manufacturing	14/934,940	11/06/2015	U.S. 10,238,705	03/26/2019
Pharmaceutical composition and method of manufacturing	16/151,436	10/04/2018	U.S. 10,639,339	05/05/2020
Pharmaceutical composition and method of manufacturing	16/359,579	03/20/2019	U.S. 10,624,940	04/21/2020
Pharmaceutical composition and method of manufacturing	16/809,958	03/05/2020	U.S. 11,266,702	03/08/2022
Pharmaceutical composition and method of manufacturing	16/809,700	03/05/2020	U.S. 11,478,520	10/25/2022
Pharmaceutical composition and method of manufacturing	16/856,492	04/23/2020	U.S. 11,344,591	05/11/2022
Pharmaceutical composition and method of manufacturing	16/856,609	04/23/2020	U.S. 11,331,358	05/17/2022
Pharmaceutical composition and method of manufacturing	18/048,954	10/24/2022		
Pharmaceutical composition and method of manufacturing	17/663,164	05/12/2022		
Pharmaceutical composition and method of manufacturing	17/663,065	05/12/2022		